Expression of Matrix Metalloproteinase 11 Gene as a Potential Biomarker of Breast Cancer
DOI:
https://doi.org/10.54536/ijphn.v2i1.6793Keywords:
Breast Cancer Biomarkers, Matrix Metalloproteinase 11 (MMP11), Tumor Microenvironment, Gene Expression AnalysisAbstract
Breast cancer is among the most prevalent malignancies and a primary contributor to cancer-related mortality in women globally. Matrix metalloproteinase 11 (MMP11) is a crucial regu-lator of tumor invasion and metastasis, degrading the extracellular matrix and correlating with an unfavorable prognosis in the majority of malignancies. Nonetheless, its expression pattern and prognostic capacity in breast cancer remain undefined. This study aimed to evaluate the expression and mutation status of the MMP11 gene in Bangladeshi breast cancer patients. Next Generation Sequencing (NGS) was conducted on tumor and adjacent normal tissues from 34 female patients recruited from Dhaka Medical College Hospital. The results indicated that the median expression of MMP11 was considerably elevated in tumor tissues (3.402 (IQR 2.097–5.133)) compared to normal tissues (1.895 (IQR 1.306–2.128), p=0.02). Among clinical variables, only the relationships of BMI, family history, age at menarche, contraceptive usage, and breastfeeding with MMP11 expression were statistically significant. Our results suggested that MMP11 was substantially expressed in breast cancer and might be a potential biomarker in breast cancer development. The identification of this gene’s role in tumor biology necessitates additional research to clarify its functional processes and therapeutic significance. These findings establish the framework for future studies that attempt to incorporate MMP11 into diagnostic or prognostic tests, with the potential to develop customized therapy methods for breast cancer patients.
References
Adrienne, G., Waks, M. D., & Eric, P. (2019). Breast cancer treatment: A review. JAMA, 321(3), 221–225.
Antoniou, A., Pharoah, P., Narod, S., Risch, H., Eyfjord, J. E., & Hopper. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations de-tected in case series unselected for family history: A combined analysis of 22 studies. American Journal of Human Genetics, 72, 1117–1130.
Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, et al. (1990). A novel met-alloproteinase gene specifically expressed in stromal cells of breast carcinomas. Na-ture, 348(6303), 699–704.
Becker, J. C., Andersen, M. H., & Schrama, D. (2013). Immune-suppressive properties of the tumor microenvironment. Cancer Immunology, Immunotherapy, 62(7), 1137–1148. https://doi.org/10.1016/j.adro2018.08.018
Behjati, S., & Tarpey, P. S. (2013). What is next-generation sequencing? Archives of Dis-ease in Childhood: Education and Practice, 98(6), 236–238.
Breast Information Core (BIC) database. Retrieved from http://research.nhgri.nih.gov/projects/bic (last visited February 2009).
Brown, G. T., & Murray, G. I. (2015). Current mechanistic insights into the roles of matrix metalloproteinases in tumor invasion and metastasis. The Journal of Pathology, 237(3), 273–281. https://doi.org/10.1002/path.4568
Chalasani, P., Kiluk, J. V., & Stopeck. (2019). Breast cancer. Medscape, 17–25.
Cheang, M. C., van de Rijn, M., & Nielsen, T. O. (2008). Gene expression profiling of breast cancer. Annual Review of Pathology: Mechanisms of Disease, 3, 67–97. https://doi.org/10.5152/ejbh.2017.3636
Chalasani, P., Kiluk, J.V., & Stopeck, A. (2019). Breast cancer. Medscape, pp. 17-25.
Cheang, M.C., van de Rijn, M., & Nielsen, T.O. (2008). Gene expression profiling of breast cancer. Annual Review of Pathology: Mechanisms of Disease, 3, 67-97. https://doi.org/10.5152/ejbh.2017.3636
De Jong, M. (2002). Genes other than BRCA1 and BRCA2 involved in breast cancer suscep-tibility. Journal of Medical Genetics, 39(4), 225–242. https://doi.org/10.1016/s0140-6736(16)324540
Denkert, C., Liedtke, C., Tutt, A., & von Minckwitz, G. (2017). Molecular alterations in tri-ple-negative breast cancer—the road to new treatment strategies. The Lancet, 389(10087), 2430-2442. https://doi.org/10.1016/s0140.6736(16)324540
Eiro, N., Cid, S., Fernández, B., Fraile, M., Sánchez, A., et al. (2019). MMP11 expression in intratumoral inflammatory cells in breast cancer. Histopathology, 75(6), 916-930. https://doi.org/10.4161/onci.24010
Forazi, A.R., & Chowdhury, B.R.K. (2015). Incidence of breast cancer in Bangladesh. Inter-national Cancer Nursing News. https://doi.org/10.1371/journal.pone.0270417
Foulkes, W.D., Smith, I.E., & Reis-Filho, J.S. (2010). Triple-negative breast cancer. New England Journal of Medicine, 363(20), 1938-1948. https://doi.org/10.4172/2161-1041.s2-001
Fu, J., Khaybullin, R., Zhang, Y., Xia, A., & Qi, X. (2015). Gene expression profiling leads to discovery of correlation of matrix metalloproteinase 11 and heparanase 2 in breast cancer progression. BMC Cancer, 15(1), 1-10.
González de Vega, R., Clases, D., Fernández-Sánchez, M.L., Eiró, N., González, L.O., et al. (2019). MMP-11 as a biomarker for metastatic breast cancer by immunohistochemi-cal-assisted imaging mass spectrometry. Analytical and Bioanalytical Chemistry, 411, 639-646.
Gonzalez-Angulo, A.M., Timms, K.M., & Liu, S. (2011). Incidence and outcome of BRCA mutation in unselected patients with triple-negative breast cancer. Clinical Cancer Research, 17, 1082-1089. https://doi.org/10.1158/1078-0432ccr-102560
Hall, J.M., Lee, M.K., & Newman, B. (1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 250, 1684-1689.
Hossain, M.S., Ferdous, S., & Karim-Kos, H. (2014). Breast cancer in South Asia: A Bang-ladeshi perspective. The International Journal of Cancer Epidemiology Detection and Prevention, 38, 465-470.
Irvin, W.J., & Carey, L.A. (1990). What is triple-negative breast cancer? European Journal of Cancer Oxford, England, 44, 2799-2805.
Johnson, D., Clases, D., Fernández-Sánchez, M.L., Eiró, N., González, L.O., et al. (2022). Quantitative multiplexed analysis of MMP-11 and CD45 in metastatic breast cancer tissues by immunohistochemistry-assisted LA–ICP–MS. Metallomics, 14(8), 80-85.
Kim, H.S., Kim, M.G., & Kim, D.H. (2021). High MMP-11 expression associated with low CD8+ T cells decreases the survival rate in patients with breast cancer. PLoS One, 16(5), e0252052.
King, M.C., Marks, J.H., & Mandell, J.B. (2003). Breast and ovarian cancer risks due to in-herited mutation in BRCA1 and BRCA2. Science, 302(5645), 643-646.
Köhrmann, A., Kammerer, K.M., Dietl, J., & Anacker, J. (2009). Expression of matrix met-alloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer, 9(1), 1-20.
Konstantopoulou, I., Rampias, T., & Ladopoulou, A. (2008). Greek BRCA1 and BRCA2 mu-tation spectrum: Two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Research and Treatment, 107, 431-441.
Lei, X., Lei, Y., Li, J.K., Du, W.X., Li, R.G., Yang, J., et al. (2020). Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Letters, 470, 126-133.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Raisa Ferdous, Sumaya Najnin, Aminur Rahman
This work is licensed under a Creative Commons Attribution 4.0 International License.
